Morphosys sees over $1 billion in sales from MOR 103: CEO
FRANKFURT (Reuters) – German biotech company Morphosys expects its upcoming rheumatism drug MOR 103 to generate sales of more than $1 billion per year, if it succeeds in getting marketing approvals, its chief executive told Reuters. “The market for rheumatism medications has a volume of $15 billion to $20 billion annually and there are a few ones which have sales of several billions of dollars,” Simon Moroney said in an interview published on Friday. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply